Cadavid D - Search Results

1

Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.

Wolansky LJ, Haghighi MH, Sevdalis E, Cook SD, Sethi N, Liu J, Joseph G, Tulloch K, Cadavid D. Wolansky LJ, et al. Among authors: cadavid d. J Neuroimaging. 2005 Jul;15(3):289-90. doi: 10.1177/1051228405277339. J Neuroimaging. 2005. PMID: 15951416 Clinical Trial. No abstract available.

2

Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI.

Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SD. Wolansky LJ, et al. Among authors: cadavid d. J Neuroimaging. 2015 May-Jun;25(3):379-83. doi: 10.1111/jon.12241. Epub 2015 Apr 13. J Neuroimaging. 2015. PMID: 25867798 Clinical Trial.

3

Clinical consequences of MRI activity in treated multiple sclerosis.

Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. Cadavid D, et al. Mult Scler. 2011 Sep;17(9):1113-21. doi: 10.1177/1352458511405375. Epub 2011 May 25. Mult Scler. 2011. PMID: 21613336 Clinical Trial.

4

Impact of inflammation on brain volume in multiple sclerosis.

Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Cheriyan J, et al. Among authors: cadavid d. Arch Neurol. 2012 Jan;69(1):82-8. doi: 10.1001/archneurol.2011.674. Arch Neurol. 2012. PMID: 22232347 Clinical Trial.

5

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.

Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. Cadavid D, et al. J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1337-43. doi: 10.1136/jnnp.2008.171090. Epub 2009 Aug 16. J Neurol Neurosurg Psychiatry. 2009. PMID: 19687024 Clinical Trial.

6

Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging.

DeBevits JJ 4th, Munbodh R, Bageac D, Wu R, DiCamillo PA, Hu C, Wang L, Naismith RT, Karimeddini D, Dhib-Jalbut S, Redko S, Cook SD, Cadavid D, Wolansky L. DeBevits JJ 4th, et al. Among authors: cadavid d. Invest Radiol. 2020 Oct;55(10):629-635. doi: 10.1097/RLI.0000000000000663. Invest Radiol. 2020. PMID: 32898355

7

Serum levels of CXCL13 are elevated in active multiple sclerosis.

Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, Cadavid D. Festa ED, et al. Among authors: cadavid d. Mult Scler. 2009 Nov;15(11):1271-9. doi: 10.1177/1352458509107017. Epub 2009 Oct 5. Mult Scler. 2009. PMID: 19805441 Clinical Trial.

8

Heterogeneity in longitudinal evolution of ring-enhancing multiple sclerosis lesions.

Qian P, Cadavid D, Wolansky LJ, Cook SD, Naismith RT. Qian P, et al. Among authors: cadavid d. Ann Neurol. 2011 Oct;70(4):668-9; author reply 669-70. doi: 10.1002/ana.22622. Ann Neurol. 2011. PMID: 22028230 Free PMC article. No abstract available.

9

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL. Brown RA, et al. Among authors: cadavid d. Neurology. 2016 Aug 30;87(9):905-11. doi: 10.1212/WNL.0000000000003043. Epub 2016 Jul 29. Neurology. 2016. PMID: 27473139 Free PMC article. Clinical Trial.

10

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD. Cadavid D, et al. Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11. Neurology. 2009. PMID: 19279320 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

125 results

Search Page